Amplia Therapeutics (ASX:ATX) is an Australian biotechnology company developing the best-in-class FAK inhibitor narmafotinib (AMP945). A Phase 1b/2a trial of narmafotinib in metastatic pancreatic cancer is underway (NCT05355298) where the drug is dosed prior to standard-of-care gemcitabine and nab-paclitaxel. Recruitment is open at sites in Melbourne, Sydney, and Brisbane.